Megan Skiendel: Long week — but also, weirdly, a good research week? Which usually means I found the thing that doesn't fit and I can't let it go.
Zara Reyes: Okay, what doesn't fit.
Megan Skiendel: Two sets of scientists study caloric restriction in rhesus monkeys — our closest practical model — and one team, University of Wisconsin-Madison, finds the restricted animals survive better and get less age-related disease. The other team, National Institute on Aging, runs a parallel study and finds no lifespan extension at all. Same species. Both rigorous.
Zara Reyes: Wait — same species, same intervention, different answer?
Megan Skiendel: Different answer. And look, there are explanations — diet composition, the age at which the animals started restriction, how the control groups were being fed. But the fact that those variables are enough to flip the conclusion tells you something about how fragile the underlying signal might be in longer-lived animals.
Zara Reyes: For context though — this intervention has ninety years of backing. Clive McCay at Cornell in the 1930s, rats on reduced caloric intake living significantly longer than controls. That's the founding data that launched all of this.
Megan Skiendel: Rats in the thirties. Then decades of replication. And then you get to primates and the picture — actually, no, it doesn't just blur, it splits.
Zara Reyes: So caloric restriction for people who haven't lived inside this research: it's a 20 to 40 percent reduction in calorie intake, nutritionally complete — enough protein, micronutrients, fiber — not starvation. The claim is that this fundamentally changes how fast you age.
Megan Skiendel: That's the promise. And it's a very old promise dressed in increasingly sophisticated mechanistic clothing right now.
Zara Reyes: Which is exactly why the primate contradiction matters so much. Like — the wellness industry is not pricing in two major studies pointing opposite directions.
Megan Skiendel: No, it's pricing in one of them. The one that confirms what people want to sell.
Zara Reyes: So the real question today is whether CR is a genuine aging lever that we just can't measure cleanly yet — or whether the effect itself dissolves as you move toward animals that actually live as long as we do.
Megan Skiendel: And what makes that question so hard to dismiss is the sheer breadth of where the effect shows up. Yeast. Nematodes. Fruit flies. Fish. Rodents. Dogs. Primates. That's not one lineage having a weird metabolic quirk — that's a pattern that predates complex animal life.
Zara Reyes: Wait — yeast? Like, single-cell yeast?
Megan Skiendel: Fifty to three hundred percent lifespan extension in yeast. Nematodes, fruit flies — same story. These are organisms with completely different metabolisms, completely different lifespans. And the same lever works.
Zara Reyes: The way I keep thinking about this, the analogy that actually clicks for me: it's like a dimmer switch on a furnace. You turn down how hard the engine runs, and the parts just last longer. Doesn't matter if the engine is a fruit fly's or a monkey's. The mechanic is the same.
Megan Skiendel: That's genuinely the right frame. And what it implies — I mean, it gets strange here — is that whatever CR is touching, it was already there before multicellular life existed.
Zara Reyes: Which means this isn't a species trick. This is something sitting underneath all of it.
Megan Skiendel: A core aging process. Not a metabolic accident of any one lineage. The dimmer switch exists in yeast, and we're running a version of the same circuit.
Zara Reyes: But here's where I keep getting stuck — the breadth of the pattern is almost too clean. Like, 50 to 300 percent lifespan extension in yeast and nematodes. Rhesus monkeys? Maybe one to five years estimated. That's not a refinement as you move up the chain, that's — actually, wait, that might be the whole point.
Megan Skiendel: Say more.
Zara Reyes: The furnace analogy works both ways. A fruit fly's engine runs hot and fast — turn it down 20 percent and you've bought proportionally huge gains. A primate's engine is already running slower, more regulated, more redundancy built in. Same dimmer, but the baseline is different.
Megan Skiendel: So the conservation of the mechanism is real — the nutrient-sensing circuitry is genuinely ancient — but the ceiling of the effect shrinks because longer-lived animals already evolved partial versions of the protection CR is delivering artificially.
Zara Reyes: Which is lowkey the most uncomfortable finding in this whole space. The pattern that makes CR look universal might also explain exactly why it'll be modest in us.
Megan Skiendel: And that's exactly where I want to go next — because if it's not one switch, what is it actually? Like, mechanically. What is CR doing at the molecular level that produces this across ninety years of organisms?
Zara Reyes: mTORC1. That's what keeps coming back to me.
Megan Skiendel: Walk me through it.
Zara Reyes: Mechanistic target of rapamycin complex 1. It's basically the cell's abundance sensor. Calories are high, mTORC1 is active, cell goes into growth mode. Calories drop, mTORC1 gets inhibited, and that's — actually that's when the interesting stuff starts. That inhibition is what triggers autophagy.
Megan Skiendel: The cellular cleanup. Damaged proteins, worn-out organelles — the cell starts eating its own debris rather than building new stuff.
Zara Reyes: Right — but that's not the only thing firing. AMPK activates at the same time. Sirtuins — NAD+-dependent, they're regulating DNA repair and metabolic stress response. IGF-1 signaling drops. Oxidative stress goes down because you're just running the metabolic engine slower, producing fewer reactive oxygen species.
Megan Skiendel: And here's what I don't think gets said clearly enough — those aren't parallel levers. They're a network. AMPK suppresses mTORC1 directly. Sirtuins are modulating many of the same stress-response genes that autophagy touches. The nodes are triggering each other.
Zara Reyes: Wait, so when you restrict calories you're not flipping one switch — you're basically firing the whole board simultaneously?
Megan Skiendel: All at once. And that's — honestly, that's why rapamycin is such an interesting and also humbling case. It's an mTORC1 inhibitor, hits that one node really precisely. And it does extend lifespan in mice. But it's not CR. You're not getting the full AMPK cascade, the sirtuin activation, the IGF-1 suppression, the oxidative stress reduction — you're getting one thread of the network, not the whole thing.
Zara Reyes: So the mimetics problem is actually a network problem. You can't replicate CR with a single drug because CR isn't doing a single thing.
Megan Skiendel: And the nodes amplify each other. You inhibit mTORC1, autophagy goes up — but AMPK being active also suppresses mTORC1 further. It's not additive, it might be closer to multiplicative. Which — I mean, that's the part that makes me genuinely uncertain whether any pharmaceutical route ever matches what the actual restriction does.
Zara Reyes: Lowkey the most inconvenient design feature in the whole space. The mechanism is real, the nodes are druggable — and the network might still be untouchable.
Megan Skiendel: Which makes what CALERIE actually found in humans the next critical question — because that's where we find out if any of this network activity translates to a measurable human outcome, or whether the signal shrinks to something almost invisible. And the answer is more complicated than either side wants to admit.
Zara Reyes: But the signal shrinking — that's actually where CALERIE lands, and it's more specific than I think people realize. This is the big U.S. randomized controlled trial, funded by the National Institute on Aging, run partly at Pennington Biomedical Research Center. Non-obese adults, BMI 22 to 27.9, twenty-four months. The mechanism fires — adiponectin goes up, ceramide species drop, glycemic control improves. Like, the adiponectin–ceramide axis is real. C16:0, C18:0, C24:0 — those ceramides linked to insulin resistance, they go down. So the network is doing something.
Megan Skiendel: And the lifespan number?
Zara Reyes: One to five years estimated. Against 50 to 300 percent in yeast. That's — I mean, that's not a gradual slope down the chain, that's basically a cliff.
Megan Skiendel: And the wellness narrative completely erases the 'one to five' part. You don't build a fasting protocol brand around 'maybe one year if everything aligns.'
Zara Reyes: No but — there's also a cost side that almost nobody's pricing in. CALERIE documented bone density loss, increased infection vulnerability, impaired wound healing, cold sensitivity, hunger, reproductive disruption. That's not a side effect list, that's the protocol eating into systems that are running fine.
Megan Skiendel: Which — honestly, that changes the arithmetic completely. One to five years on the back end, against real costs on the front end that hit people who aren't sick.
Zara Reyes: Think about who's actually doing this. A 44-year-old nurse, three months into a structured CR protocol she found in a longevity newsletter, sitting in a cold break room at midnight, too hungry to sleep between shifts. Does the one-to-five-year estimate account for someone working nights? Like — does CALERIE's population even include that?
Megan Skiendel: It does not. BMI 22 to 27.9, non-obese, controlled conditions. That nurse is not the trial subject.
Zara Reyes: Right — but she's the person buying the newsletter.
Megan Skiendel: And here's where the primate split becomes the real warning label. If we can't settle whether CR extends lifespan in rhesus monkeys — and the disagreement comes down to what the control group was eating and how old the animals were when they started — then the idea that we have the human protocol dialed in is genuinely wishful.
Zara Reyes: Wait — the control group diet is potentially the whole story?
Megan Skiendel: The Wisconsin monkeys' controls were eating a less healthy baseline diet. The NIA controls were eating better. So the Wisconsin group looked like CR extended lifespan — but what if it just looks powerful when you're comparing against a bad baseline? That means CR might only work if you were already eating poorly. Which — frankly, that reframes everything about human translation.
Zara Reyes: So the mechanistic signal in CALERIE is real, the adiponectin numbers are real — but whether the lifespan gain is coming from CR itself or just from correcting a bad baseline is still an open question. And that's the thing the wellness industry absolutely cannot sell.
Megan Skiendel: Which is exactly what makes the mimetics pitch so seductive right now. Rapamycin, metformin, resveratrol, the GLP-1R agonists, NAD+ modulators — each one is essentially saying: we found the node, we can hit it pharmacologically, you don't have to starve. And I understand why that's attractive. But the network argument we just built is the exact reason I can't fully buy it.
Zara Reyes: Because hitting one node isn't firing the board.
Megan Skiendel: Rapamycin is a real drug — it's already in clinical use as an immunosuppressant, mTORC1 inhibitor, that part is not speculative. But the longevity question is whether you block that one node and get the cascade, or whether the cascade only happens because CR is — I mean, it's doing everything simultaneously. AMPK, sirtuins, IGF-1 suppression, oxidative stress reduction. Rapamycin is one thread. And the cost isn't small — you are trading CR's costs for immunosuppression. That's not a known quantity in healthy people taking it long-term for longevity. That's a different and much less characterized set of harms.
Zara Reyes: So the honest version of the mimetics pitch is: we don't actually know if a single drug hitting one node replicates what whole-body restriction does when everything fires together. And that's — lowkey, that's the question nobody in the longevity space wants to sit with.
Megan Skiendel: Honestly? I can't settle it. Whether the coordinated simultaneous engagement of those pathways is load-bearing — like, is the simultaneity itself the mechanism — or whether each node is independently contributing and we just happen to get all of them at once with CR. Because if it's the latter, a stack of mimetics might actually get you there. But if it's the former — if the nodes amplify each other and that amplification is the thing — then no single drug, no combination, fully replicates it.
Zara Reyes: And we genuinely don't know which one it is.
Megan Skiendel: No. And that's — actually, that's maybe where the healthspan frame is doing the most useful work. If the lifespan question is genuinely unresolvable right now, and the mimetics question is genuinely unresolvable, then maybe the frame that's actually honest is: can we protect the years we have? Not adding years, just keeping the ones that are already there free from the disease and decline. CALERIE showed real signals in glycemic control, in the ceramide axis. That's not nothing.
Zara Reyes: It's a quieter claim. But it might be the only one the evidence actually supports. I'll take it.
